Dementia with Lewy Bodies Consortium

路易体痴呆症联盟

• 批准号: 10291600
• 负责人: JAMES Bruce LEVERENZ
• 金额: $ 9.44万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10291600
• 关键词: Address; Alzheimer' s Disease; Autopsy; Behavioral; Biological Markers; Clinical; Clinical assessments; Cognition; Collection; Communities; Country; Data; Data Management Resources; Dementia; Dementia with Lewy Bodies; Diagnosis; Disease; Elderly; Enrollment; Ensure; Failure; Foundations; Funding; Future; Image; Image Analysis; Impaired cognition; Lewy Body Dementia; Lewy Body Disease; Link; Motor; National Institute of Neurological Disorders and Stroke; National Institute on Aging; Parkinson Disease; Parkinson' s Dementia; Participant; Pathology; Patients; Prognosis; Research; Research Personnel; Resources; Sampling; Standardization; Therapeutic Studies; Time; United States; Update; Vascular Diseases; biomarker development; clinical Diagnosis; cooperative study; follow-up; neuroimaging; neuropathology; programs; progression marker; translational study; treatment response

Project Summary It has been estimated that 1.4 million people in the United States suffer from Lewy body dementia (LBD), including both dementia with Lewy bodies (DLB) or Parkinson's disease with dementia (PDD). Patients with LBD suffer from cognitive decline, sometimes linked to Alzheimer's disease (AD), and the motor and behavioral changes seen in Parkinson's disease (PD). Unfortunately, the diagnosis of LBD can be difficult, particularly in those DLB patients that present with cognitive impairment prior to motor or marked behavioral changes. Biomarkers for LBD are few and their value in diagnosis, prognosis, and for treatment response is limited. Impediments to biomarker development in LBD have included small subject numbers, a lack of systematic patient characterization, and a failure to perform longitudinal follow up with autopsy. Both AD and PD have benefited from a number of large “consortiums” that have advanced research by leveraging the strengths of several groups of research centers to combine efforts with standardized approaches to the study of the disease. One good example is the Alzheimer's Disease Centers (ADC) program, funded by the National Institute on Aging, where over 30 research centers across the United States have agreed to a standardized approach to the diagnosis and characterization of patients with AD. Other similar programs include the Alzheimer's Disease Cooperative Study (ADCS), Alzheimer's Disease Neuroimaging Initiative (ADNI), the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarker Program (PDBP), and the Parkinson's Progression Marker Initiative (PPMI). Fortunately, the latter two PD programs have included more systematic clinical assessments and collection of biofluids and imaging data relevant to cognition in PD. Recently, a pathology component has been added to the PPMI project. No similar program exists for DLB. The objective of this proposal is to establish a consortium of centers for the study of DLB with a large number of subject enrolled, systematic assessments (compatible with AD and PD programs), collection of biofluids and imaging data, and ultimately autopsy. The DLB consortium (DLBC) would create the necessary foundation for biomarker development and have the secondary benefit of creating an ongoing subject sample available for additional translational and therapeutic studies. We have brought together nine centers with expertise in the Lewy body disorders and with strong connections to the Lewy body dementia research and general community to participate in the DLBC. This group of investigators has collaborated extensively together for many years and will provide the foundation for this much needed resource.

项目摘要 据估计，美国的痴呆症（LBD）有140万人 将痴呆症与痴呆症（DLB）或痴呆症患者一起 LBD患有认知能力下降，有时与阿尔茨海默氏病（AD）和运动和运动有关 不幸的是，帕金森氏病（PD）的行为变化。 特别是在那些在运动或明显行为之前出现认知障碍的DLB患者中 更改LBD的生物标志物很少 有限的。 LBD中生物标志物开发的障碍包括少量主题数量，缺乏系统性 患者表征，无法进行纵向进行纵向进行尸检。 从许多大型“财团”中受益，这些大型“财团”通过利用优势来进行高级研究 几组研究中心，将敌方与标准化方法相结合以进行研究 疾病。 老化研究所，美国有30个研究中心拥有贸易界的标准化。 ED患者的诊断和表征的方法。 阿尔茨海默氏病合作研究（ADCS），阿尔茨海默氏病神经影像倡议（ADNI） 国家神经系统疾病与中风研究所（NINDS）帕金森氏病生物标志物计划 （PDBP）和帕金森的进度标记倡议（PPMI）。 已经包括了更系统的临床评估，并收集了与之相关的生物流体和成像数据。 PD中的认知已添加到PPMI项目中 存在DLB。 该提案的目的是建立一个大量DLB研究中心联盟 受试者的系统评估（与AD和PD计划兼容），生物流体的收集和 成像数据和最终尸检。 生物标志物开发，并具有创建可用于用于的正在进行的主题样本的次要好处 其他翻译和治疗研究。 路易的身体障碍，与路易痴呆症研究和一般社区有着密切的联系 参加DLBC。 并将为急需的资源提供基础。